Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy regimens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Chemotherapy regimens. Displaying page 3 of 40.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003995-36 Sponsor Protocol Number: STAD-1 Start Date*: 2006-10-04
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A MULTICENTER RANDOMIZED PHASE III STUDY COMPARING FIXED DOSES WITH TOXICITY-ADJUSTED DOSES OF STANDARD CHEMOTHERAPY WITH CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY ADVANCED SMALL CELL LUNG CA...
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059514 Small cell lung cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002850-38 Sponsor Protocol Number: PI-0327-2013 Start Date*: 2015-05-21
    Sponsor Name:FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA
    Full Title: EFFICACY AND SAFETY OF EARLY POSTOPERATIVE CHEMOTHERAPY INTRAPERITONEAL (EPIC) WITH PACLITAXEL IN THE RADICAL SURGERY TREATMENT OF OVARIAN PERITONEAL CARCINOMATOSIS
    Medical condition: ovarian peritoneal carcinomatosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003535-11 Sponsor Protocol Number: 2017-003535-11 Start Date*: 2018-09-21
    Sponsor Name:Erasmus MC [...]
    1. Erasmus MC
    2. Maasstad Hospital
    Full Title: The added value of the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment
    Medical condition: Paclitaxel-induced hypersensitivity reactions
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000222-51 Sponsor Protocol Number: 06_DOG05_44 Start Date*: 2007-09-07
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: Short CHemo RadioImmunotherapy in Follicular Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma
    Medical condition: Follicular Lymphoma First and second relapse of Follicular Lymphoma grade 1, 2, 3a.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004976-18 Sponsor Protocol Number: NO16853 Start Date*: 2006-06-05
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: An Open-Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and/or Metastatic Breast...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016940-38 Sponsor Protocol Number: REO018 Start Date*: 2010-04-26
    Sponsor Name:Oncolytics Biotech Inc.
    Full Title: Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000793-19 Sponsor Protocol Number: SOLTI-1203 Start Date*: 2014-10-20
    Sponsor Name:SOLTI
    Full Title: A Phase II, Randomized Study of T DM1 versus T DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer.
    Medical condition: Progressive or recurrent, locally advanced unresectable or metastatic HER2+ breast carcinoma in patients who have not received previous chemotherapy for the advanced disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004519-32 Sponsor Protocol Number: AVANeo1 Start Date*: 2005-11-28
    Sponsor Name:Medical University Vienna, Dept. of surgery
    Full Title: A randomised controlled pilot study of the efficacy of adding bevacizumab to gemcitabine as neoadjuvant treatment for locally advanced non metastatic pancreatic cancer - Neo-Avastin
    Medical condition: locally advanced non-metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012019-17 Sponsor Protocol Number: BO22280 Start Date*: 2009-09-02
    Sponsor Name:F. Hoffmann - La Roche Ltd
    Full Title: A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemother...
    Medical condition: Locally advanced, inflammatory or early stage HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) PT (Completed) GR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001904-10 Sponsor Protocol Number: PM0259CA301J1 Start Date*: 2004-09-15
    Sponsor Name:Pierre Fabre Médicament represented by IRPF
    Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ...
    Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001949-34 Sponsor Protocol Number: E7389-G000-305 Start Date*: 2006-10-02
    Sponsor Name:Eisai Limited
    Full Title: A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously T...
    Medical condition: Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (Completed) CZ (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012595-27 Sponsor Protocol Number: A8081007 Start Date*: 2010-01-20
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (...
    Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003287-39 Sponsor Protocol Number: PRO-105 Start Date*: 2017-07-05
    Sponsor Name:NuCana plc
    Full Title: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer
    Medical condition: Platinum-resistant epithelial cancer of the ovary, fallopian tube or primary peritoneum (here termed ‘ovarian cancer’), who have been treated with 3 or more prior chemotherapy regimens.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002725-74 Sponsor Protocol Number: COU-AA-004 Start Date*: 2007-07-16
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002033-21 Sponsor Protocol Number: NKV102551 Start Date*: 2006-09-11
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonis...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008448 Chemotherapy induced emesis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IE (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003656-35 Sponsor Protocol Number: E7389-G000-211 Start Date*: 2006-03-14
    Sponsor Name:Eisai Limited
    Full Title: A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to...
    Medical condition: Locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001526-19 Sponsor Protocol Number: BO27798 Start Date*: 2011-12-28
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients wi...
    Medical condition: Metastatic HER2-positive adenocarcinoma of the stomach or gastro-esophageal junction.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001790-86 Sponsor Protocol Number: PIX306 Start Date*: 2012-12-24
    Sponsor Name:CTI Biopharma, Corp.
    Full Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or a...
    Medical condition: Treatment of Patients with Aggressive B-cell Non-Hodgkin Lymphoma , who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    19.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) CZ (Completed) DK (Prematurely Ended) BG (Prematurely Ended) PL (Completed) BE (Completed) AT (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-004021-98 Sponsor Protocol Number: MO 18458 Start Date*: 2005-05-12
    Sponsor Name:ROCHE
    Full Title: A single arm phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with...
    Medical condition: metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052358 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 19:44:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA